iX Biopharma Ltd. (SGX:42C)

Singapore flag Singapore · Delayed Price · Currency is SGD
0.1180
-0.0050 (-4.07%)
At close: Oct 30, 2025
-4.07%
Market Cap103.99M
Revenue (ttm)7.77M
Net Income (ttm)-10.14M
Shares Out888.84M
EPS (ttm)-0.01
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume4,658,700
Average Volume20,589,880
Open0.1220
Previous Close0.1230
Day's Range0.1170 - 0.1220
52-Week Range0.0150 - 0.1360
Beta0.31
RSI75.51
Earnings DateNov 10, 2025

About iX Biopharma

iX Biopharma Ltd., a specialty pharmaceutical and nutraceutical company, develops, manufactures, and commercializes therapies for the treatment of acute and breakthrough pain, and other health conditions in Singapore, the United States, China, and Australia. The company operates through Specialty Pharmaceutical and Nutraceutical segments. It offers Wafesil and Silcap for the treatment of male erectile dysfunction; and Xativa, a sublingual cannabidiol wafer, as well as Hypera, a sublingual tetrahydrocannabinol wafer for chronic pain, anxiety, an... [Read more]

Industry Pharmaceutical Preparations
Founded 2004
Employees 35
Stock Exchange Singapore Exchange - Catalist
Ticker Symbol 42C
Full Company Profile

Financial Performance

In 2025, iX Biopharma's revenue was 7.77 million, an increase of 30.34% compared to the previous year's 5.96 million. Losses were -10.14 million, -6.05% less than in 2024.

Financial Statements

News

There is no news available yet.